Editorially Independent content supported with advertising by Novartis and Alcon.
Arshad M. Khanani, MD
Show Description +
Arshad M. Khanani, MD, outlines the case of a patient whose wet AMD requires treatment every 4 to 6 weeks. The patient was diagnosed in 2010 and has been administered more than 60 doses of various anti-VEGF agents. The patient underwent therapy with brolucizumab (Beovu, Novartis), and began to experience improved vision and extended duration intervals. Hear a panel of experts discuss this case on the New Retina Radio miniseries The Art of Drug Choice: Wet AMD and the Latest Data.
Posted: 10/22/2020
Arshad M. Khanani, MD
Arshad M. Khanani, MD, outlines the case of a patient whose wet AMD requires treatment every 4 to 6 weeks. The patient was diagnosed in 2010 and has been administered more than 60 doses of various anti-VEGF agents. The patient underwent therapy with brolucizumab (Beovu, Novartis), and began to experience improved vision and extended duration intervals. Hear a panel of experts discuss this case on the New Retina Radio miniseries The Art of Drug Choice: Wet AMD and the Latest Data.
Posted: 10/22/2020
New Retina Radio
All video episodes of this series are also available as podcast episodes on New Retina Radio.
Please log in to leave a comment.